- TRADE NAME: Xospata (Astellas)
- INDICATIONS: indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
- CLASS: Kinase inhibitor
- HALF-LIFE: 113 hours
- FDA APPROVAL DATE: 11/28/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Escitalopram, Fluoxetine, Sertraline - PREGNANCY: can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 12/11/2024
